PPMO's as therapeutic modulators for myotonic dystrophy type 1

類似資料

• Proteomic evaluation of Pip6a-PMO treatment for myotonic dystrophy type 1
  著者:: Holland, A, 等
  出版事項: (2018)
• Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice
  著者:: Klein, AF, 等
  出版事項: (2019)
• Application of antisense conjugates for the treatment of myotonic dystrophy type 1
  著者:: Stoodley, J, 等
  出版事項: (2023)
• Systemic PPMO-mediated dystrophin expression in the Dup2 mouse model of Duchenne muscular dystrophy
  著者:: Liubov V. Gushchina, 等
  出版事項: (2022-12-01)
• Cardiac manifestations in myotonic dystrophy type 1
  著者:: A. G. Klementieva, 等
  出版事項: (2024-09-01)